Why was I denied Wegovy by Aetna?

Aetna typically denies Wegovy coverage when a prior authorization (PA) fails to meet clinical criteria, or if your specific employer-sponsored plan excludes weight-loss drugs entirely.

📊 Common Aetna Denial Reasons

• Employer Exclusion (EMP-EXCL): Your employer chose to carve out and completely exclude weight-management medications from your specific benefit plan.
• Missing Prior Authorization Criteria (PA-NOT-MET / BMI-NOT-MET): Your documented Body Mass Index (BMI) did not meet Aetna's threshold (typically a BMI ≥ 30, or ≥ 27 with a weight-related comorbidity like high blood pressure or high cholesterol).
• Incomplete Documentation: Your doctor’s submission lacked required clinical notes, such as proof of participating in a structured weight-loss or diet program for 3 to 6 months.
• Step Therapy Required (STEP-REQ): Your plan mandates that you first try and "fail" alternative, lower-cost weight loss or foundational medications before approving Wegovy.
• Non-Formulary (NF): Wegovy is not listed on your specific plan's preferred drug list, or an alternative GLP-1 is favored.

💡 What You Can Do Next

1. Check your Explanation of Benefits (EOB): Locate the specific denial reason code on page 1 or 2 of your denial letter from Aetna or CVS Caremark.
2. Contact HR or Aetna: Verify whether your employer plan has a blanket exclusion for weight loss drugs; if it is an employer carve-out, Aetna's internal appeals cannot override it.
3. File an Appeal: If it is a clinical or documentation denial, ask your physician to submit an appeal with updated medical records, proof of comorbidities, or previous weight-loss program history.

Aetna covers Wegovy on many commercial plans when specific clinical and prior authorization requirements are met, though coverage ultimately depends on your specific employer or individual plan design.

To check your specific plan coverage and formulary details, you can log in through the Aetna Member Website.

Prior Authorization (PA) Requirements for Weight Loss

When prescribed for chronic weight management, Aetna generally requires prior authorization showing the following criteria:

• Adult BMI Criteria: A baseline body mass index (BMI) of 30 kg/m² or higher (obesity), OR a BMI of 27 kg/m² or higher (overweight) with at least one weight-related comorbid condition (such as high blood pressure, type 2 diabetes, or high cholesterol).
• Pediatric BMI Criteria (Ages 12–17): An initial BMI at or above the 95th percentile standardized for age and sex.
• Lifestyle Program History: Documented participation in a structured weight management program—including a reduced-calorie diet, increased physical activity, and behavioral modification—for at least 6 months prior to starting the medication.
• Ongoing Maintenance/Renewal: For continued coverage after initial approval (typically 7 months for initial approval, 12 months for renewal), adults must demonstrate at least a 5% reduction in baseline body weight after 3 months on a stable maintenance dose.

Alternative Coverage Pathways

Aetna may also approve Wegovy under separate FDA-approved indications:

• Cardiovascular Risk Reduction: Requires a baseline BMI of 27 or higher, no diagnosis of type 2 diabetes, a reduced-calorie diet and physical activity, and established cardiovascular disease (such as a history of heart attack, stroke, or symptomatic peripheral arterial disease).
• Liver Disease (MASH): Requires specialist consultation (gastroenterologist or hepatologist), a reduced-calorie diet and exercise, and confirmed stage F2–F3 liver fibrosis.

Note: Plans with an explicit "weight-loss medication exclusion" (common in many self-funded employer plans) will deny coverage for weight management regardless of medical necessity. Standard Medicare Advantage and Part D plans also exclude weight-loss drugs by federal law unless tied to specific non-weight loss indications.

You can still access Wegovy after an insurance denial by appealing the decision, using manufacturer self-pay programs, or utilizing alternative discount options.

File an Insurance Appeal

• Ask for the reason: Request a formal denial letter from your insurance company to see why they rejected coverage.
• Submit a prior authorization (PA): Ask your doctor to submit a detailed PA or a letter of medical necessity. This letter should highlight weight-related conditions like high blood pressure, heart disease, or pre-diabetes.
• Request a formal peer-to-peer review: Have your prescribing doctor call your insurance medical director to explain why Wegovy is essential for your health.

Use Manufacturer Self-Pay Programs

• Check NovoCare options: The drug manufacturer offers self-pay and promotional pricing through the NovoCare Program if your commercial plan denies coverage.
• Review out-of-pocket tiers: Self-pay monthly prices for starting injection doses are around $199, moving to $349 per month for maintenance doses, while oral tablet options start around $149 per month depending on the exact dosage.

Explore Discount Cards and Alternatives

• Prescription savings cards: Use discount tools like GoodRx to compare local retail pharmacy cash prices and coupons.
• Use HSA/FSA funds: Pay for out-of-pocket prescriptions using pre-tax dollars from a Health Savings Account (HSA) or Flexible Spending Account (FSA).
• Discuss alternative medications: Ask your doctor if other FDA-approved weight-loss or GLP-1 medications on your insurer’s formulary list are covered by your specific policy.

Insurance companies often deny coverage for Wegovy because they classify anti-obesity medications as lifestyle or cosmetic treatments rather than medical necessities.

Common Reasons for Denial

• Plan Exclusions: Many commercial insurance plans and employers completely exclude weight loss drugs from their coverage benefits. The Affordable Care Act does not mandate coverage for anti-obesity medications.
• High Financial Cost: Because over 100 million people qualify for these treatments, insurers limit coverage to control massive short-term drug expenditures.
• Prior Authorization Gaps: Insurers frequently deny requests if the submitted paperwork fails to document a specific Body Mass Index (BMI) threshold, such as a BMI of 30 or higher (or 27 with weight-related health conditions).
• Missing Comorbidity Data: Claims are often rejected if patient records do not explicitly list weight-related conditions like high blood pressure, type 2 diabetes, or sleep apnea.
• Step Therapy Rules: Plans may require patients to try and fail older, less expensive weight-loss or metabolic drugs before approving a newer GLP-1 medication.
• Lack of Lifestyle Proof: Insurers often require documentation showing that a patient participated in a structured diet and exercise program for 3 to 6 months.

Most Aetna plans cover Wegovy in 2026 for chronic weight management if your specific employer or policy includes weight-loss drug benefits and you meet clinical prior authorization criteria.

Coverage and Formulary Status

• Preferred Status: On CVS Caremark standard, Advanced Control, and Value formularies (Aetna’s pharmacy benefit manager), Wegovy serves as a preferred weight-loss GLP-1 option.
• Employer Carve-Outs: Preference does not guarantee universal coverage. Many employer-sponsored commercial plans explicitly exclude or "carve out" anti-obesity medications entirely.
• Cardiovascular Pathway: If your plan excludes weight-loss drugs, you may still qualify through alternative pathways if you have established cardiovascular disease, as Wegovy holds FDA approval for cardiovascular risk reduction.

Prior Authorization (PA) Criteria

To secure approval for weight loss, Aetna typically requires:

• An adult BMI of 30 or higher, or 27 or higher with at least one weight-related condition (such as high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea).
• Documented participation in a lifestyle/behavioral modification program (reduced-calorie diet and increased physical activity).
• Confirmation that you are not combining Wegovy concurrently with other GLP-1 medications.
• Renewals: Continuation of coverage typically requires proof of at least 5% weight loss from baseline after the initial authorization period.

Costs and Copays

• Out-of-Pocket Expenses: Standard commercial copays for preferred brand drugs generally range from $25 to $100 per month, though some newer tiered structures or specific state/employer plan designs feature copays up to $200 per month.
• Deductibles: If your plan has a high deductible, you must pay the negotiated CVS Caremark rate out-of-pocket until that deductible is met.
• Savings Cards: Eligible commercial members can apply manufacturer savings cards (like NovoCare) to lower monthly expenses.

You can verify your exact formulary status and drug tier by logging into your member portal via the Aetna Find a Medication tool or by calling the number on your insurance card.